Active, currently enrolling
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1
NCT No.: NCT03785249
Study Type: INTERVENTIONAL
Phase:
Phase I, Phase II
Region: California - Northern
Acronym:
Official Title
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1
Purpose
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
Detailed Description
Eligibility Criteria
Inclusion Criteria
|
Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation
; Unresectable or metastatic disease
; Standard treatment is not available or patient declines; first-line treatment for NSCLC for certain cohorts
; Adequate organ function
|
Exclusion Criteria
|
History of intestinal disease or major gastric surgery or inability to swallow oral medications
; Other active cancer
|
Keywords and/or Specific Medical Conditions
Sponsors
|